Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120696 | 0.86 | — | — | |
| SCHEMBL28213446 | 0.82 | KDM4E (0.37) | KDM4EKMT2A | |
| SCHEMBL5222511 | 0.82 | ALOX15 (0.36) | ALOX15 | |
| SCHEMBL28275959 | 0.81 | KDM4E (0.36) | KDM4EKMT2A | |
| SCHEMBL28236679 | 0.80 | ALOX15 (0.34) | ALOX15 | |
| SCHEMBL25475349 | 0.78 | TSHR (0.34) | KDM4EKMT2AOPRM1 | |
| Hydrochloric Acid SCHEMBL3493468 | 0.78 | KDM4E (0.34) | KDM4EKMT2A | |
| SCHEMBL3335475 | 0.77 | OPRM1 (0.32) | KDM4EKMT2AOPRM1 | |
| SCHEMBL26785429 | 0.77 | OPRM1 (0.35) | KDM4EKMT2AOPRM1 | |
| SCHEMBL25475257 | 0.75 | OPRM1 (0.31) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115448923-B | Pyrimidine-fused ring compound, preparation method and application thereof | 上海青煜医药科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| CN-115448923-A | Pyrimido-cyclic compounds, process for their preparation and their use | 青煜医药研发(上海)有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-110156786-B | Pyrimido-cyclic compounds, process for their preparation and their use | 青煜医药研发(上海)有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-114341124-A | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2022-04-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348467-A1 | Heteroaryl Derivative, Preparation Method Therefor, And Use Thereof | PTPN11, PTPN1, PTPN7 | KDM4E 1231/4885KMT2A 1292/4885OPRM1 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.